Browsing Tag
relapsed
1 post
Mivavotinib for relapsed/refractory B-cell lymphoma
Kaplan–Meier curve for estimated median DOR in the DLBCL combined cohort (response-evaluable population). Credit: 2023 Gordon et al. In a new research paper published in Oncotarget, researchers report an updated analysis from a phase I study of the spleen tyrosine kinase (SYK) and FMS-like tyrosine kinase 3 inhibitor mivavotinib. They present data for the overall
February 1, 2023